Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs.

An analysis of real-world data pulled from Truveta’s electronic health records of 30 U.S. health care systems found that patients treated for pulmonary embolism (PE) using Boston Scientific Corp.’s ...

Please provide your email address to receive an email when new articles are posted on . Catheter-directed thrombolysis was linked to less major bleeding than mechanical thrombectomy in patients with ...

Ekos (Bothell, Washington) reported that the FDA has cleared its EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices Each year, approximately 350,000 patients in the United ...

PE is a blood clot that causes a blockage in one or more pulmonary arteries that bring blood to the lungs, and is the third leading cause of cardiovascular mortality. 1 Current medical guidelines for ...